Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

T. Nukiwa, , A. Inoue, K. Kobayashi, M. Maemondo, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, Y. Saijo, H. Yoshizawa, S. Morita, K. Hagiwara, Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. Journal of Clinical Oncology. ,vol. 29, pp. 7519- 7519 ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.7519

Alan Berezov, Natalie Minkovsky, BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Current opinion in investigational drugs. ,vol. 9, pp. 1336- ,(2008)

Rodenhuis S, ras and human tumors. Seminars in Cancer Biology. ,vol. 3, pp. 241- 247 ,(1992)

Ozgur Cem Erkin, Jhingook Kim, Jin Seok Ahn, Jungsuk An, Myung Ju Ahn, Jinwon Seo, Keunchil Park, Young Mog Shim, Young Kee Shin, Yoon La Choi, Kyung Song, Sanghui Park, Chang Ok Sung, Joungho Han, High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histology and Histopathology. ,vol. 27, pp. 197- 207 ,(2012) , 10.14670/HH-27.197

Patrick C Ma, Gautam Maulik, James Christensen, Ravi Salgia, c-Met: Structure, functions and potential for therapeutic inhibition Cancer and Metastasis Reviews. ,vol. 22, pp. 309- 325 ,(2003) , 10.1023/A:1023768811842

Andreas Gschwind, Oliver M. Fischer, Axel Ullrich, The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews Cancer. ,vol. 4, pp. 361- 370 ,(2004) , 10.1038/NRC1360

Alice Tsang Shaw, D Ross Camidge, Jeffrey A. Engelman, Benjamin J. Solomon, Eunice Lee Kwak, Jeffrey W. Clark, Ravi Salgia, Geoffrey Shapiro, Yung-Jue Bang, Weiwei Tan, Lesley Tye, Keith D. Wilner, Patricia Stephenson, Marileila Varella-Garcia, Kristin Bergethon, A. John Iafrate, Sai-Hong Ignatius Ou, Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Journal of Clinical Oncology. ,vol. 30, pp. 7508- 7508 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.7508

James Chih-Hsin Yang, Martin H. Schuler, Nobuyuki Yamamoto, Kenneth John O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey V Orlov, Chun-Ming Tsai, Michael J. Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz N.H. Shah, Dan Massey, Robert M. Lorence, Mehdi Shahidi, Lecia V. Sequist, LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology. ,vol. 30, pp. LBA7500- LBA7500 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.LBA7500

Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088

Ian M. Ahearn, Kevin Haigis, Dafna Bar-Sagi, Mark R. Philips, Regulating the regulator: post-translational modification of RAS Nature Reviews Molecular Cell Biology. ,vol. 13, pp. 39- 51 ,(2012) , 10.1038/NRM3255